RxDoctor Payments Data

Monica Hauger, NP

Nurse Practitioner · Trafalgar, INNPI 1659460541

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $32,280 of the $46,633 with a category attached, or 69.2%. 10 manufacturers reported payments, led by Novo Nordisk at 50.9% of the total. Reporting peaked in 2021 at $18,149 and has fallen 75.9% since, to $4,368 in 2024. Among nurse practitioner clinicians in IN with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$46,633in general payments, 2019–2025

Across 132 payments — averaging $353.28 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$24K
  • Lilly USA, LLC$15K
  • AbbVie$7K
  • Biohaven Pharmaceuticals, Inc.$821
  • Eli Lilly$350
  • Ironshore Pharmaceuticals Inc.$119
  • plus $60 from 4 others

What the payments were for

  • Consulting fees$6,46314%
  • Speaking & faculty fees$32,28069%
  • Travel & lodging$5,80112%
  • Food & beverage$2,0854%
  • Education$40%

General payments by program year

21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$46,633 in reported general payments places this provider in the 95th percentile of 2,724 nurse practitioner providers in Indiana.

See all nurse practitioner providers in Indiana

Medicare billing

Part B allowed, 2024
$15,132
Medicare patients
53
Services billed
248

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide29$37,049
MounjaroTirzepatide19$20,212
InvokanaCanagliflozin20$16,387
JardianceEmpagliflozin15$13,979
EliquisApixaban17$10,352
EntrestoSacubitril/Valsartan12$8,124
Desvenlafaxine Succinate ErDesvenlafaxine Succinate55$4,743
Fluticasone-SalmeterolFluticasone Propion/Salmeterol32$3,681
Rosuvastatin Calcium88$1,430
Valsartan19$777
Levothyroxine Sodium72$757
Metoprolol Succinate41$547
Duloxetine Hcl19$518
Venlafaxine Hcl ErVenlafaxine Hcl14$456
Bupropion XlBupropion Hcl16$444

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$23,758$37,04929 claims
Lilly USA, LLCMounjaro$14,876$20,21219 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,724 nurse practitioner providers in Indiana.

Other nurse practitioner in Trafalgar

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →